IP Library Granted Patent US 9,005,924
Granted Patent B2
US 9,005,924 · App. 13/765,302 · Granted Apr 14, 2015

Acceptor framework for CDR grafting

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,924
App. No.
13/765,302
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

Claims (12)

1. A method of humanizing a rabbit immunobinder, the method comprising:

(a) grafting the CDR H1, CDR H2 and CDR H3 sequences from a donor rabbit immunobinder into the human heavy chain acceptor framework comprising SEQ ID NO: 1; and

(b) grafting the CDR L1, CDR L2 and CDR L3 sequences from a donor rabbit immunobinder into a human light chain acceptor framework into a light chain acceptor framework that has at least 85% identity to SEQ ID NO: 2.

2. A method of humanizing a rabbit immunobinder, the method comprising:

(a) grafting the CDR H1, CDR H2 and CDR H3 sequences from a donor rabbit immunobinder into the human heavy chain acceptor framework comprising SEQ ID NO: 1; and

(b) grafting the CDR L1, CDR L2 and CDR L3 sequences from a donor rabbit immunobinder into a human light chain acceptor framework into a light chain acceptor framework that has at least 85% identity to SEQ ID NO: 2, and

(c) substituting framework residues in one or both of the human heavy chain acceptor framework and the human light chain framework with framework residues of the donor rabbit immunobinder.

3. The method of claim 2 , wherein the heavy chain acceptor framework has a substitution at one or more of heavy chain amino positions 12, 103 and 144 (AHo numbering).

4. The method of claim 3 , wherein the substitution at one or more of positions 12, 103 and 144 are selected from the group consisting of:

(a) Serine (S) at position 12;

(b) Threonine (T) at position 103; and

(c) Threonine (T) at position 144.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2022
From: CELL MEDICA INC.
To: CELL MEDICA, INC.
Reel/Frame 060529/0195 →
CHANGE OF NAME Recorded Jul 18, 2022
From: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
To: ESBATECH, A NOVARTIS COMPANY LLC
Reel/Frame 060529/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2022
From: ESCHER, DOMINIK
To: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
Reel/Frame 059553/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2022
From: ESBATECH, A NOVARTIS COMPANY LLC
To: CELL MEDICA SWITZERLAND AG
Reel/Frame 059553/0144 →
SECURITY INTEREST Recorded Jul 7, 2021
From: CELL MEDICA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 056782/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2021
From: CELL MEDICA SWITZERLAND AG
To: CELL MEDICA INC.
Reel/Frame 054988/0114 →